Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

サイズ 価格(税別)  
JPY 50796.00
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(64)

カスタマーフィードバック(13)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M1zBVmN6fG:2b4jpZ{BCe3OjeR?= NVroWIN{OTBibl2= M4rNbFczKGh? NFvMPW1FVVOR M1jqcXBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> M3zpVVI1QTByOEez
HT-29 NYTRS5JsS3m2b4TvfIlkKEG|c3H5 NXe5O5lYOTBibl2= M3u4ZVczKGh? NUnSdWxtTE2VTx?= MkjtVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 NWfrVYRlOjR7MEC4O|M>
HT-29 MWLDfZRwfG:6aXOgRZN{[Xl? NGOxN5EyOCCwTR?= MYK3NkBp NFTQVJdFVVOR MkLzVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> M1\mXlI1QTByOEez
PC3 MWfLbY5ie2ViQYPzZZk> M{nJb|ExOCCwTR?= M{\RbVEhcA>? Mkm5SG1UVw>? MlTXVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= M1OxdFIyQTd6Nkiz
PC3 M4rweWtqdmG|ZTDBd5NigQ>? MVGxNFAhdk1? NUnJPWxHOSCq M37YUGROW09? NYnU[nZpTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= M3HZe|IyQTd6Nkiz
PC3 M3LVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;lNU42KM7:TR?= NXnjSJNVOSCq NY\zeXViTE2VTx?= NXXjfINJUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N NGnsOWUzOTl5OE[4Ny=>
HEK293 MmHOSpVv[3Srb36gRZN{[Xl? MlGyNVAxKG6P MnWyPEBp NWTwVW56TE2VTx?= MmPkTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P MoHQNlE2Ozl|MEG=
BT-20 M2nkVGtqdmG|ZTDBd5NigQ>? NYrneZZsOjBizszN M1\KbGROW09? MYDEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? MYKyNVM2OzV3MR?=
U937 NWXrTlZMSW62aXLhZ5RmemmjbDDBd5NigQ>? MWG1NEDPxE1? Mln4OFghcA>? Mkn3SG1UVw>? MXzJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? MojhNlEyPDJzME[=
U937 NWXjOXJ1SW62aXLhZ5RmemmjbDDBd5NigQ>? NWLOfZdRPTBizszN MWS0PEBp NGPKeW9FVVOR NGTSNlBFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| MkXhNlEyPDJzME[=
U937 MmrHRY51cWKjY4TldolidCCDc4PhfS=> MmX1OVAh|ryP NWTaTVY1PDhiaB?= MXjEUXNQ M4HZfmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ NEjDT2ozOTF2MkGwOi=>
MCF-7 MYLBeZRweGijZ4mgRZN{[Xl? MWSzNEBvVQ>? M1GyNlQhcA>? M1HDPWROW09? MYnJcoR2[2W|IHH1eI9xcGGpeR?= M3\HN|IxODJ6MUO0
U87MG Mon6T4lv[XOnIFHzd4F6 NEe4NIgyKM7:TR?= M4TWWVYhcA>? M{X4PWROW09? NIPPfpdRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= M13k[FE6QDR6NEC0
U87MG NFy3Wm5McW6jc3WgRZN{[Xl? MWOxJO69VQ>? MUW2JIg> NH\Cc4NFVVOR NED3VFNRd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> NGKzXlgyQTh2OESwOC=>
U87MG MWTLbY5ie2ViQYPzZZk> NXnNR2U5OSEQvF2= Mor4OkBp NGn5T3hFVVOR MUPEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MUexPVg1QDRyNB?=
U87MG NGDhOW9McW6jc3WgRZN{[Xl? MVWxJO69VQ>? MoWzOkBp NWrQVmZXTE2VTx?= NV3De3BCTG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w M1fMe|E6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb MmrBRZV1d3CqYXf5JGF{e2G7 NWXKfJhPOC5{IN88US=> MX6yOEBp NVXiXXVmTE2VTx?= NHSwbXlKdmS3Y3XzJIF2fG:yaHHnfS=> M3nZdlE5OzlzOUS5
COS7 cells expressing EGFP-LC3 MXHBeZRweGijZ4mgRZN{[Xl? Mlf5NE4zKM7:TR?= NILENWYzPCCq MYrEUXNQ MlLPTY5lfWOnczDheZRweGijZ4m= MUOxPFM6OTl2OR?=
H4 Mn\MSpVv[3Srb36gRZN{[Xl? NVfJVnFOOC5{IN88US=> M1TRRVI1KGh? NI\zUJRFVVOR NUL4bXgxUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? MUmxPFAzPDV6NB?=
HeLa M4\MOGZ2dmO2aX;uJGF{e2G7 MXGxNFAhdk1? MnjqN|YhcA>? NUnxRXhqTE2VTx?= MoX6TY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> MYWxO|U3OzN6NR?=
HeLa Mkj3SpVv[3Srb36gRZN{[Xl? NVrEWVc3OTByIH7N NV\JUo9jOzZiaB?= NXPVNFlWTE2VTx?= NXfuN4VMUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w MnjBNVc2PjN|OEW=
HeLa NIm5OYJHfW6ldHnvckBCe3OjeR?= M2D3ZVExOCCwTR?= MY[zOkBp M3zCeWROW09? NV6yPIpVUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NUPUdGVkOTd3NkOzPFU>
SYF MVXGeY5kfGmxbjDBd5NigQ>? M4XOflExOCCwTR?= NVfydnNtOjRiaB?= MmrFSG1UVw>? M4PQNmlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NVrvO3hXOTd3NkOzPFU>
SYF NWKyd4hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXafIJQOTByIH7N NEf2RVUzPCCq M1\uTmROW09? NGDRTZhKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz M{L6eVE4PTZ|M{i1
HEK293T NEXQeHpCdnSrdnnyZYwhSXO|YYm= MkeyNUBvVQ>? M3HJNFQh\A>? MmHDSG1UVw>? Mnn3TY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= MYWxO|Q5PTVyMR?=
HEK293T NUO4OpJnSW62aY\pdoFtKEG|c3H5 MmnLNUBvVQ>? M{XEVlQh\A>? NXzjS|Q{TE2VTx?= MVfJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NFjLZ5MyPzR6NUWwNS=>
PBMC NFLXN|dHfW6ldHnvckBCe3OjeR?= MXKxJI5O NHn4bI0yPCCm NWPBepgyTE2VTx?= NVr4OFh[WmWmdXPld{BES1J3IHTlcpNqfHl? M4PH[FE4PDh3NUCx
PBMC NXHab3JjTnWwY4Tpc44hSXO|YYm= NWPlNolTOSCwTR?= M1y1XVE1KGR? NVnrT2pUTE2VTx?= Ml;4SI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> M3jWW|E4PDh3NUCx
HEK293 cells NWLtNII4U2mwYYPlJGF{e2G7 MYO1NEBvVQ>? NX:wS3N3PDVibXnu MV\EUXNQ MUPJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O NVz5NphTOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MorXSpVv[3Srb36gRZN{[Xl? M4LUO|ExOCCwTR?= MYG0JIg> MULEUXNQ NGrhS3dKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? NH:5T5gyPzF{OEK2Ni=>
Human mixed lymphocyte Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW1JI5O NGHuNppFVVOR NGnMb4xKSzVyPUGuOkBvVS5? M3XmOFE3OTh3OE[1
Lewis rat lymph node cells MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXkOUDPxE1? Ml;VSG1UVw>? NF\hRVdKSzVyPUKuOkDPxE1? NEH4coEyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLBbFU2OTBibl2= NHPGZZM4OiCq NXPhS|B[TE2VTx?= NGTrU21KdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N M164OlExODJzOUS4
MRK-nu-1 NGPvXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD1cFNjUUN3ME2wMlg1PSCyTR?= NFXH[YVUSU6JRWK=
OCUB-M MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVwMkSgdG0> NVPIV5BjW0GQR1XS
SF539 M4nTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3mTWM2OD1zMT62JJBO M2O5dXNCVkeHUh?=
ES4 NXjhcIV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e1b2lEPTB;MkGuOUBxVQ>? MVLTRW5ITVJ?
RL95-2 NF;HZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD1zMEegdG0> MYfTRW5ITVJ?
LC-2-ad MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT2TWM2OD12MkOgdG0> NXrnPIVXW0GQR1XS
Daudi NG\uUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvmTWM2OD12M{SgdG0> MUHTRW5ITVJ?
NTERA-S-cl-D1 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL0TWM2OD12NEOgdG0> MoG0V2FPT0WU
OS-RC-2 NXPlNHFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCxTWM2OD14NUKgdG0> MWTTRW5ITVJ?
VA-ES-BJ NHHkNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTd{MzDwUS=> NHjG[Y1USU6JRWK=
GR-ST NEm3bVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTh2NjDwUS=> MX7TRW5ITVJ?
SW872 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;TTWM2OD16NE[gdG0> M4HWR3NCVkeHUh?=
NOS-1 NFjxTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[5TWM2OD16N{GgdG0> MVPTRW5ITVJ?
MC116 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nIbmlEPTB;OUi1JJBO NYDiVpdWW0GQR1XS
NCI-H1355 NHTOZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ObYVKSzVyPUGuNFEhdk1? MknuV2FPT0WU
RPMI-8226 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnKOmJKSzVyPUGuNVkhdk1? NXXNSmRyW0GQR1XS
TE-15 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS1R3lTUUN3ME2xMlM3KG6P MXXTRW5ITVJ?
Ramos-2G6-4C10 M2m5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwNE[gcm0> MkD1V2FPT0WU
KU812 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwMEGgcm0> MXPTRW5ITVJ?
EW-1 M{H5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwMUegcm0> NFTobnNUSU6JRWK=
KS-1 NXLFTHYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGxb2JMUUN3ME2yMlQ2KG6P MnX0V2FPT0WU
SK-LMS-1 NUjWOlFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluwTWM2OD1{LkS5JI5O NUnx[mVIW0GQR1XS
TGBC1TKB M17zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTWTWM2OD1{Lk[5JI5O M3[3OHNCVkeHUh?=
TE-6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJwN{egcm0> NFjU[|NUSU6JRWK=
ETK-1 NGTFbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPMNmZpUUN3ME2yMlgzKG6P NF7OWY1USU6JRWK=
BE-13 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7ZUnpKSzVyPUKuPVkhdk1? NHzzb4NUSU6JRWK=
A3-KAW NX7aWmZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJwOUmgcm0> NIPzW5FUSU6JRWK=
TE-10 M2ryO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITCNolKSzVyPUOuN{BvVQ>? NHXlPHBUSU6JRWK=
DOHH-2 NFrIOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HKd2lEPTB;Mz6zOUBvVQ>? MUTTRW5ITVJ?
ES6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwNEOgcm0> NEXyPVBUSU6JRWK=
OPM-2 MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTTTWM2OD12LkG1JI5O NYLhfVM{W0GQR1XS
SH-4 NXjmWohqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK2[plKSzVyPUSuN|Qhdk1? M3HtW3NCVkeHUh?=
NB13 NGS4T4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DGcmlEPTB;ND6zOkBvVQ>? NWO1dGZOW0GQR1XS
HUTU-80 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTRwNEKgcm0> MoK4V2FPT0WU
CCRF-CEM MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TmS2lEPTB;ND65OEBvVQ>? M4DnR3NCVkeHUh?=
TGBC24TKB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfSRYFKSzVyPUWuOVEhdk1? MVPTRW5ITVJ?
697 NXPJVYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXtRVNlUUN3ME22MlI5KG6P MkOxV2FPT0WU
J-RT3-T3-5 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTZwNE[gcm0> NX[wVm9YW0GQR1XS
KALS-1 NGi2WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LLT2lEPTB;Nj61OkBvVQ>? MVLTRW5ITVJ?
no-10 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\zW5lJUUN3ME23MlI6KG6P NFXFcHpUSU6JRWK=
SK-NEP-1 NVPSdWNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRThwN{mgcm0> NFTZNnBUSU6JRWK=
L-540 NIL2cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXETWM2OD1zMD60NkBvVQ>? NX7PeYlWW0GQR1XS
JiyoyeP-2003 M3jNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS1NpUxUUN3ME2xNE46PCCwTR?= NGPHSXRUSU6JRWK=
HH NVXUV4hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj3TWM2OD1zMT6zPUBvVQ>? NWLRV4NCW0GQR1XS
SR M2rNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3njb2lEPTB;MUGuOFUhdk1? MoS1V2FPT0WU
QIMR-WIL MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\yc2VKSzVyPUGxMlg2KG6P NH;VVXdUSU6JRWK=
A4-Fuk MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PBZmlEPTB;MUOuNVIhdk1? NV;p[mZuW0GQR1XS
CESS M1LFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jNZ2lEPTB;MUOuNVMhdk1? M3e5UHNCVkeHUh?=
KE-37 M2GzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y1fWlEPTB;MU[uNFchdk1? NEHMW|dUSU6JRWK=
SK-UT-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rRcGlEPTB;MU[uPFEhdk1? MUXTRW5ITVJ?
SIG-M5 NVq2d5QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn4NmlKSzVyPUG3MlI2KG6P Ml\oV2FPT0WU
HT NGXkdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF5Lk[gcm0> M1jKdXNCVkeHUh?=
DEL NFzuOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCxOohIUUN3ME2xO{46QSCwTR?= MWjTRW5ITVJ?
SK-PN-DW MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7vPHU6UUN3ME2yNE4zOyCwTR?= NH;FcIdUSU6JRWK=
RPMI-8402 NIrIPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHXTWM2OD1{MT63O{BvVQ>? NXe3V4Y2W0GQR1XS
RPMI-6666 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vBemlEPTB;MkSuOFIhdk1? NVLZWGJTW0GQR1XS
NCI-H720 NGLN[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjETWM2OD1{NT60NUBvVQ>? MWXTRW5ITVJ?
EW-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ4Lki3JI5O NYnrV2JQW0GQR1XS
BL-70 M4f1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzE[4hiUUN3ME2yPE4{QCCwTR?= NHzwdHNUSU6JRWK=
SF126 NInCOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLGTWM2OD1|MD6zPEBvVQ>? NVH1SnlKW0GQR1XS
BC-1 NHjXfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH2TWM2OD1|MT6yOkBvVQ>? MnrKV2FPT0WU
MHH-PREB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17D[2lEPTB;M{KuOFQhdk1? M3;YPHNCVkeHUh?=
A101D NXe3eFlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyx[Jl2UUN3ME2zNk43OiCwTR?= NETSXYpUSU6JRWK=
NMC-G1 NF3S[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrySnJKSzVyPUOzMlY4KG6P MVLTRW5ITVJ?
LB1047-RCC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjXPGtKSzVyPUO0MlY6KG6P MkThV2FPT0WU
EM-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDuUXVKSzVyPUO4MlU{KG6P M{DZdHNCVkeHUh?=
COLO-684 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\xTWM2OD1|OT64JI5O M4qwTHNCVkeHUh?=
Becker Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\CV5ZCUUN3ME20NU4xPSCwTR?= M2C5V3NCVkeHUh?=
BL-41 M4nHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PSVmlEPTB;NEOuOlYhdk1? MX\TRW5ITVJ?
MDA-MB-134-VI NGHmem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\KSnlsUUN3ME20OE4xOiCwTR?= NX3SeHZzW0GQR1XS
L-363 M1n6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PDXWlEPTB;NESuO|Mhdk1? NFTFb2lUSU6JRWK=
ECC4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTR2Lke4JI5O M4j0d3NCVkeHUh?=
A388 M2PZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS3TWM2OD12ND64NkBvVQ>? MoDQV2FPT0WU
HEL M2n3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;DbVhKSzVyPUS5Mlc6KG6P NH7H[JJUSU6JRWK=
RKO NInaO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTVyLkK5JI5O NUDIV5ZpW0GQR1XS
KINGS-1 NHTmfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvwNHUzUUN3ME21NU42PSCwTR?= MYHTRW5ITVJ?
EB-3 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPJeVZHUUN3ME21Nk43PyCwTR?= NGK2bXVUSU6JRWK=
ARH-77 M2PTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTV{Lkigcm0> NFfxVHpUSU6JRWK=
GCIY M{XMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTV|LkS2JI5O M13XbnNCVkeHUh?=
NCI-H1304 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTCTWM2OD13Nz6yNkBvVQ>? MUjTRW5ITVJ?
KARPAS-299 NIC0VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfzO3hoUUN3ME22NU45OiCwTR?= MXzTRW5ITVJ?
IA-LM MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj0TWM2OD14OD6xN{BvVQ>? MXnTRW5ITVJ?
GI-1 NIPGbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT2TWM2OD15MD6zPUBvVQ>? MnLlV2FPT0WU
TE-11 M2L2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrGcnlKSzVyPUe3MlE4KG6P NUX1VI92W0GQR1XS
LS-411N M{nKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTd5LkW3JI5O MUnTRW5ITVJ?
no-11 NIK5cJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3TVWZKSzVyPUizMlI1KG6P NXvLPYlyW0GQR1XS
MV-4-11 Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnqTlVlUUN3ME24N{44OyCwTR?= NIHwVYVUSU6JRWK=
BV-173 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPuRYYyUUN3ME24N{46PyCwTR?= NXe2NIJwW0GQR1XS
CMK NIjyNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPQN5lKSzVyPUi0MlE3KG6P NU[0fo1jW0GQR1XS
LC4-1 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[yUXBKSzVyPUi2MlczKG6P M1jBS3NCVkeHUh?=
COR-L279 NID4NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInMTY9KSzVyPUi3MlI2KG6P MljSV2FPT0WU
NCI-H209 M3vFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fTemlEPTB;OEeuOFEhdk1? MnnhV2FPT0WU
Raji M2HHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPJTWM2OD16OT63NkBvVQ>? NHvpS5hUSU6JRWK=
LB996-RCC NIn5dIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvpRXFGUUN3ME25N{41OyCwTR?= MULTRW5ITVJ?
NCI-H526 NXPuSndVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fiWGlEPTB;OUOuOVkhdk1? MmrsV2FPT0WU
KGN Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTl4LkK5JI5O M4rTeHNCVkeHUh?=
MOLT-4 NYDi[4RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTl4Lke5JI5O M1mxRXNCVkeHUh?=
PF-382 M4HXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTl4Lke5JI5O MnPsV2FPT0WU
BC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn2UFQ5UUN3ME25PU4yQCCwTR?= MmD3V2FPT0WU
KARPAS-422 NWnTSlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;kTWM2OD1zMEKuNFkhdk1? NEDWW4FUSU6JRWK=
SBC-1 NIjzXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37BUGlEPTB;MUC3Mlc2KG6P NXm3dVVUW0GQR1XS
LC-1F NHnLWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XIOGlEPTB;MUC4MlA2KG6P NFjFcphUSU6JRWK=
GB-1 M4LYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkezTWM2OD1zMEmuNFIhdk1? MVTTRW5ITVJ?
SNB75 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHXSY5DUUN3ME2xNVkvPjlibl2= M2\3XHNCVkeHUh?=
BB65-RCC NWD3bmQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnFTWM2OD1zMUmuPVMhdk1? NInFWFlUSU6JRWK=
NCI-N87 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7uTWM2OD1zMkGuPVghdk1? NWTFe5JzW0GQR1XS
IST-MEL1 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zzVGlEPTB;MUKyMlM5KG6P M2[0UnNCVkeHUh?=
HOP-62 M2n1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF{Nj64PUBvVQ>? MV\TRW5ITVJ?
ACN M13kWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LkN2lEPTB;MUS2Mlc2KG6P NF\4UmpUSU6JRWK=
DMS-114 M1zsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq1TWM2OD1zNUCuOlchdk1? NX74e3dmW0GQR1XS
MLMA MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrvXlZ3UUN3ME2xOVkvQDhibl2= NGnBXGhUSU6JRWK=
HT-144 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPHeGtKSzVyPUG2OU41OyCwTR?= MmnpV2FPT0WU
C2BBe1 NF3SWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrIfoFyUUN3ME2xOlcvPzZibl2= MlfLV2FPT0WU
L-428 M37LSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrNV49wUUN3ME2xO|cvPyCwTR?= M3LTZXNCVkeHUh?=
DU-4475 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\PWHpKSzVyPUG4O{43QCCwTR?= NF\GNmFUSU6JRWK=
CP67-MEL NFLpUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF7OT6zPEBvVQ>? NIPMW2ZUSU6JRWK=
MEG-01 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LzSmlEPTB;MkCxMlk3KG6P MVPTRW5ITVJ?
IST-SL2 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T1[WlEPTB;MkC4MlY{KG6P NXjqPWUzW0GQR1XS
ES8 M1zUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHxe2luUUN3ME2yNlUvQTRibl2= NHXMWYpUSU6JRWK=
COLO-800 NGT1UlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGyTG54UUN3ME2yN|UvOjhibl2= M2e1dXNCVkeHUh?=
MFH-ino M4ewR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ|NT64OEBvVQ>? NX;2fYlHW0GQR1XS
OVCAR-4 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHTVFdKSzVyPUKzO{4zPCCwTR?= MkezV2FPT0WU
PSN1 NV73XlNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ2Mj63NUBvVQ>? MYLTRW5ITVJ?
EW-12 M4ezPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHtTWM2OD1{NEOuNUBvVQ>? NWrpc2FHW0GQR1XS
HCC1599 M4X4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrDb3dKSzVyPUK2NU41PyCwTR?= M2W2OXNCVkeHUh?=
SJSA-1 NUjFSFZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzFTWM2OD1{N{GuOFYhdk1? Mlm4V2FPT0WU
ST486 NIHONZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS0TWM2OD1{OU[uNVQhdk1? MlHQV2FPT0WU
NOMO-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Xoc2lEPTB;M{CwMlIyKG6P MVjTRW5ITVJ?
MN-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrITWM2OD1|MEWuN|Ihdk1? MlLtV2FPT0WU
HCC1187 NX\GW4hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7JTWM2OD1|MEeuNlUhdk1? NEn4ZVJUSU6JRWK=
SW982 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjZbGVQUUN3ME2zNVQvPzVibl2= MkLOV2FPT0WU
LB647-SCLC NXfmUm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn3SnBKSzVyPUOyPE44OSCwTR?= MVHTRW5ITVJ?
HC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[1RndGUUN3ME2zN|UvPSCwTR?= NFSyXllUSU6JRWK=
EHEB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXuSI53UUN3ME2zN|cvPTJibl2= M{DVZnNCVkeHUh?=
TUR NX;icZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN4Mz65OUBvVQ>? M123R3NCVkeHUh?=
LU-139 M2\RS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr3TWM2OD1|N{iuNFIhdk1? M13CcnNCVkeHUh?=
NB1 M{LBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTN6ND60OUBvVQ>? M37PPXNCVkeHUh?=
BB30-HNC MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN6OD6zNkBvVQ>? M1HQe3NCVkeHUh?=
HAL-01 NFzwR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\VTWM2OD1|OEmuNlYhdk1? Mlj5V2FPT0WU
K5 NX7NWXlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m0dGlEPTB;NEGxMlM4KG6P NHThUodUSU6JRWK=
MZ2-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnIdYZ2UUN3ME20NVMvPjRibl2= NETBWYZUSU6JRWK=
RXF393 M3\yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrvU4pEUUN3ME20NVYvPDVibl2= NVjqWFJQW0GQR1XS
NCI-H1648 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TXZWlEPTB;NEG3MlU{KG6P MlqyV2FPT0WU
TE-12 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDBNGRPUUN3ME20N|QvOjZibl2= MYfTRW5ITVJ?
EoL-1- MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTR|Nz65PEBvVQ>? MYfTRW5ITVJ?
JAR NYnQXlRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTR|OD62NkBvVQ>? Mny2V2FPT0WU
DSH1 NFvUe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXHTWM2OD12NUiuPVEhdk1? NHm4ZlJUSU6JRWK=
NCI-H187 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTQRXdKSzVyPUS2Nk45OSCwTR?= MoLNV2FPT0WU
HCE-4 M1T5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTR5Nz62OkBvVQ>? M2T6W3NCVkeHUh?=
8-MG-BA Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPmSopyUUN3ME21PFEvPTJibl2= NVfDcpEyW0GQR1XS
KLE MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTV6NT6yJI5O MUfTRW5ITVJ?
KNS-42 NGTJbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTV6Nj64NUBvVQ>? NVe2TmlWW0GQR1XS
MSTO-211H M1PW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKyVZBKSzVyPU[wPU44PCCwTR?= NGTkeFZUSU6JRWK=
GDM-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOxdW5xUUN3ME22NVQvODlibl2= MYDTRW5ITVJ?
TE-1 NGXWUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorxTWM2OD14NE[uNVIhdk1? NUnyWotCW0GQR1XS
BT-474 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nL[2lEPTB;NkS3MlA3KG6P NFnCeZdUSU6JRWK=
KARPAS-45 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ueWlEPTB;NkS3MlYhdk1? NYfZRVRLW0GQR1XS
MOLT-16 NHLPd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTZ2Nz65N{BvVQ>? MVHTRW5ITVJ?
KURAMOCHI MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\uTWM2OD14NUeuOVEhdk1? MnvEV2FPT0WU
K-562 M{\BdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHhS5dKSzVyPU[2PU42OSCwTR?= NE\jbHZUSU6JRWK=
EKVX MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnkTWM2OD14N{KuO|Ehdk1? MkTLV2FPT0WU
GAK MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXubmVlUUN3ME22O|UvOyCwTR?= NXWzcVExW0GQR1XS
NCI-SNU-5 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW2TWM2OD14OUCuNFEhdk1? MXnTRW5ITVJ?
NCI-H2126 NIrCToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\ve2lEPTB;N{K2Mlg4KG6P MoLmV2FPT0WU
CTV-1 NWTTRWpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPZbFVKSzVyPUe0OE46KG6P NXz6SFdoW0GQR1XS
SW962 NVzQTI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTd2OD60OEBvVQ>? NH;KTGhUSU6JRWK=
MONO-MAC-6 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W0WGlEPTB;N{W2Mlk{KG6P MVzTRW5ITVJ?
NCI-H748 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXYeZJKSzVyPUe1PE46QSCwTR?= MmP5V2FPT0WU
NCI-H524 M2ewb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTd6MD63N{BvVQ>? NH60WZJUSU6JRWK=
LS-123 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjiTWM2OD15OUWuOlkhdk1? NUC0PIRIW0GQR1XS
NB7 NVr5U|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XXOGlEPTB;OEG0MlE1KG6P NVnYcpdxW0GQR1XS
LS-1034 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm2TWM2OD16MkiuPVghdk1? MnjvV2FPT0WU
TE-5 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OyeWlEPTB;OEizMlU3KG6P NVTHWlhmW0GQR1XS
A704 NF3S[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7sTWM2OD16OUmuNVUhdk1? NX;PUnFoW0GQR1XS
TK10 NV;aNYpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTlzNj6wN{BvVQ>? NG\EeHNUSU6JRWK=
NCI-H345 MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\JclRKSzVyPUm0N{4zOiCwTR?= NXnORWZxW0GQR1XS
CGTH-W-1 NWXXdYdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPZTWM2OD17NEiuNVMhdk1? NFPUd|RUSU6JRWK=
NCI-H510A NXnPNZZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jrfmlEPTB;OUi1MlEzKG6P NYPYfodQW0GQR1XS
NCI-H1963 M2HWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfYTWM2OD1zLkCzNlkzKM7:TR?= MmL0V2FPT0WU
SCC-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwMEO0NVQh|ryP M{Dz[HNCVkeHUh?=
EW-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmizTWM2OD1zLkC4O|Q{KM7:TR?= M{G4NnNCVkeHUh?=
CPC-N NYPObIRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmwSlZ4UUN3ME2xMlA5QCEQvF2= NYXuW5BVW0GQR1XS
NCI-H1417 M2XsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\oTWM2OD1zLkGyNlYh|ryP NGG5SFJUSU6JRWK=
DG-75 M37sXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHjTWM2OD1zLkG2Nlg2KM7:TR?= NEXHeGNUSU6JRWK=
HD-MY-Z MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzhZ5d[UUN3ME2xMlE3PDF4IN88US=> Ml2xV2FPT0WU
ATN-1 NHLCWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzvU29QUUN3ME2xMlI3OjB7IN88US=> M2LBOHNCVkeHUh?=
KM-H2 NVXD[3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\1TWM2OD1zLkK2OFA5KM7:TR?= MnzVV2FPT0WU
NCI-H2081 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS3WYtoUUN3ME2xMlI3PjN5IN88US=> M{G4T3NCVkeHUh?=
HL-60 NVHGXYZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DHUWlEPTB;MT6yOlk2QSEQvF2= NWPoWIx5W0GQR1XS
DB NWPMb4FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\oTWM2OD1zLkK3NlQzKM7:TR?= MWfTRW5ITVJ?
NCI-H1522 M2HEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7vSlBKSzVyPUGuNlg5QDdizszN MnHxV2FPT0WU
AM-38 NUX1Zph[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3qTWM2OD1zLkOwO|Ih|ryP M3jWUXNCVkeHUh?=
NCI-H446 M36zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n4[GlEPTB;MT6zNlEzOSEQvF2= NYTKXW5EW0GQR1XS
SU-DHL-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTrXYxKSzVyPUGuN|I5ODFizszN MWTTRW5ITVJ?
NH-12 NULYS4JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDaTWM2OD1zLkO2N|c1KM7:TR?= NYO1cpVVW0GQR1XS
DMS-79 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorOTWM2OD1zLkO2PFY3KM7:TR?= M4DzTXNCVkeHUh?=
NCI-H716 NXSzcYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzxfJhiUUN3ME2xMlM5QTh4IN88US=> MVvTRW5ITVJ?
ML-2 NVPlc2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwNEG1Nlkh|ryP M3rPfnNCVkeHUh?=
NB10 NXTsPVUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GwbWlEPTB;MT60OlY{OiEQvF2= NECyNnBUSU6JRWK=
ONS-76 NV7afld[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33neGlEPTB;MT61N|U3QSEQvF2= NUK1dndjW0GQR1XS
LOUCY NEDTVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\UNIZYUUN3ME2xMlU1PjV5IN88US=> MoPNV2FPT0WU
SCLC-21H NGDjdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ja[WlEPTB;MT61PFU5OiEQvF2= Mo\IV2FPT0WU
TGW M3[1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXBTWM2OD1zLk[zPVc2KM7:TR?= MV3TRW5ITVJ?
LXF-289 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLJbldSUUN3ME2xMlc{OjZ6IN88US=> MlPlV2FPT0WU
BB49-HNC NHTIZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HtW2lEPTB;MT63N|U5PiEQvF2= NGr1UIZUSU6JRWK=
NCI-H747 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfCbYNnUUN3ME2xMlc2OzR4IN88US=> MX;TRW5ITVJ?
LU-165 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXr[3RuUUN3ME2xMlg1QTh4IN88US=> MlnYV2FPT0WU
OMC-1 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH1fnpxUUN3ME2xMlk2ODZ4IN88US=> Ml\hV2FPT0WU
RCC10RGB NHTPd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqxVWhKSzVyPUGuPVU5OTdizszN NV;wdpE3W0GQR1XS
SW684 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTqZXJKSzVyPUGuPVYxQTlizszN MVTTRW5ITVJ?
TE-8 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXGTWM2OD1{LkC1OVU6KM7:TR?= NXrQRWZ2W0GQR1XS
SK-N-DZ NHrGcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF62T5lKSzVyPUKuNVMzPzRizszN MVTTRW5ITVJ?
EVSA-T NGPHVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnwXmtmUUN3ME2yMlE4OzF3IN88US=> NGHzSW1USU6JRWK=
KASUMI-1 M3PETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH3d2hKSzVyPUKuNVg5OTVizszN MnTmV2FPT0WU
NKM-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2yWlA1UUN3ME2yMlI2PDd{IN88US=> NEj6R4xUSU6JRWK=
CAL-148 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwM{O2NVQh|ryP MnPPV2FPT0WU
NCI-H64 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T1R2lEPTB;Mj6zOFI{OiEQvF2= MnT1V2FPT0WU
KNS-81-FD MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn0em9KSzVyPUKuN|Y3OiEQvF2= Mm\YV2FPT0WU
KM12 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGOzc4lKSzVyPUKuOFA5OzlizszN MY\TRW5ITVJ?
SW954 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX3eJpKSzVyPUKuOFc4PzlizszN M2W3cnNCVkeHUh?=
NCI-H1395 NInKfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\PPGlEPTB;Mj61NlY1PSEQvF2= M{XmTnNCVkeHUh?=
DJM-1 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;YTWM2OD1{Lk[wOlMh|ryP NHy2eIZUSU6JRWK=
COLO-668 NIjmVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKxc2xkUUN3ME2yMlgzPjl3IN88US=> MYfTRW5ITVJ?
NCI-H1436 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrwTWM2OD1{Lki1OlE2KM7:TR?= MlzJV2FPT0WU
LB2241-RCC NXq5Z2VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPPVYdKSzVyPUKuPFY5OzlizszN NEXJc4lUSU6JRWK=
GT3TKB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ITWM2OD1{Lki5NFU2KM7:TR?= NV\sSYlmW0GQR1XS
COLO-824 NY\3ZlNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrDTWM2OD1{Lki5O|Y5KM7:TR?= NVXYZZM{W0GQR1XS
ES1 M170cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvmboh5UUN3ME2yMlg6QDd7IN88US=> NHrocHFUSU6JRWK=
LB771-HNC NEnyTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17hbGlEPTB;Mj65NFk1PiEQvF2= M4\lNXNCVkeHUh?=
GI-ME-N M1jUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwMEC5NFQh|ryP M{jOWXNCVkeHUh?=
NALM-6 M1;6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJTZNnUUN3ME2zMlAxQTN|IN88US=> NIHXTlVUSU6JRWK=
LU-134-A NIDIU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvXTWM2OD1|LkC1OFI2KM7:TR?= M3\acHNCVkeHUh?=
DMS-153 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNwMEW4NlQh|ryP M3jsfHNCVkeHUh?=
MZ1-PC NV3MUpNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj3TWM2OD1|LkC5NFc5KM7:TR?= NHGzOIlUSU6JRWK=
NCI-H1155 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\pNWlEPTB;Mz6xNVYyKM7:TR?= MX\TRW5ITVJ?
CAS-1 NFO2fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrRcHBzUUN3ME2zMlE{PzB5IN88US=> NE\WVYpUSU6JRWK=
D-502MG NVu1fpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XZVWlEPTB;Mz6xOFM6KM7:TR?= NHzUOZdUSU6JRWK=
NCI-H2141 NY\jZYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMU21EUUN3ME2zMlE4PDV{IN88US=> MULTRW5ITVJ?
NB6 M3fCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHsPG1nUUN3ME2zMlE5OjV7IN88US=> M4na[nNCVkeHUh?=
NCCIT NHywe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLOdVBCUUN3ME2zMlIyQDB7IN88US=> MYHTRW5ITVJ?
NB69 NGTxd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPscHJXUUN3ME2zMlMyQDlzIN88US=> NIX1Z5BUSU6JRWK=
JVM-2 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPBb2xKSzVyPUOuN|Y1OzNizszN MlvYV2FPT0WU
K052 NEe0WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWntRWFbUUN3ME2zMlM4QTZ6IN88US=> MmnjV2FPT0WU
HCC2157 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLt[oFjUUN3ME2zMlU{OjJ6IN88US=> NFPNbpRUSU6JRWK=
KMOE-2 NHzoU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hz[GlEPTB;Mz61OFI1OiEQvF2= NH3FOGdUSU6JRWK=
SF268 NH;zNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNwN{G1OVQh|ryP M4fm[HNCVkeHUh?=
CHP-126 NYDEXnVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n0NGlEPTB;Mz63OlQ2QCEQvF2= M{jEVnNCVkeHUh?=
CP66-MEL NWHMfWJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrSPGhKSzVyPUOuO|kxQTRizszN M{TVfXNCVkeHUh?=
NCI-H69 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvKPZNoUUN3ME20MlAyQTN4IN88US=> NHTVV|RUSU6JRWK=
A253 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HzXGlEPTB;ND6wNlExOSEQvF2= MlTlV2FPT0WU
NB14 M2jxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;RbFQ4UUN3ME20MlExPDd7IN88US=> NVu4Z3V4W0GQR1XS
NCI-H1694 NG[4NpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwMUOxNVIh|ryP M{T4dHNCVkeHUh?=
NCI-H2196 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW4SFNKSzVyPUSuNVcyPjlizszN NGjXbolUSU6JRWK=
TE-9 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXaTWM2OD12LkG3OVgzKM7:TR?= MXHTRW5ITVJ?
D-283MED Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwMUi4OEDPxE1? NHHYN4pUSU6JRWK=
OCI-AML2 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\LOGVKSzVyPUSuNVk1QDlizszN MVHTRW5ITVJ?
D-263MG M1nLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfQcJJKSzVyPUSuNlI6PjFizszN MYfTRW5ITVJ?
MPP-89 NXuzT4FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vX[2lEPTB;ND6yO|MxPCEQvF2= NGrG[YJUSU6JRWK=
LAMA-84 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHqxW3dKSzVyPUSuN|A1OjFizszN M2fpT3NCVkeHUh?=
LB373-MEL-D M4XRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf3TWM2OD12LkO2O|g6KM7:TR?= MoTLV2FPT0WU
UACC-257 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHwUVB3UUN3ME20MlM6PTN2IN88US=> NGTRTYxUSU6JRWK=
MC-CAR MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjrfJNwUUN3ME20MlQ{QTlizszN NUT5R29kW0GQR1XS
COLO-320-HSR Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwNES0Nlch|ryP MYnTRW5ITVJ?
P30-OHK NHHDVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRwNk[1PFEh|ryP MWPTRW5ITVJ?
UACC-812 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KNFV{UUN3ME20MlY6OTZzIN88US=> NYjHbGtKW0GQR1XS
CTB-1 NFH5N3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjIUmpYUUN3ME20MlcyPTV3IN88US=> M2Due3NCVkeHUh?=
ALL-PO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnjTWM2OD12Lki0NFc4KM7:TR?= M2PBNnNCVkeHUh?=
SK-MEL-2 NUDlcHg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrEVoNKSzVyPUSuPFY6PTVizszN NHHsVndUSU6JRWK=
TC-YIK M4DwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXZTWM2OD12Lkm3PVQzKM7:TR?= MXfTRW5ITVJ?
NCI-H1882 NVLGXYJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vlW2lEPTB;NT6wNlAxOSEQvF2= NVe2WGpkW0GQR1XS
MHH-CALL-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\wWGlEPTB;NT6wOVA1OiEQvF2= NWXPclV5W0GQR1XS
U-87-MG NYKyNWZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTVwMEm0OlYh|ryP MX\TRW5ITVJ?
NCI-H1092 M2HNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe2R4lKSzVyPUWuNlY2PTVizszN M1TXVXNCVkeHUh?=
TE-441-T NX\WS2VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHSW4lRUUN3ME21MlI4QDJizszN NIL4OJNUSU6JRWK=
SK-MEL-1 NIC5foRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHziUWxKSzVyPUWuNlkxPDRizszN M4CxPHNCVkeHUh?=
EW-22 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPQTWM2OD13LkK5OFY3KM7:TR?= NEjKb5FUSU6JRWK=
MZ7-mel M4n4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvRTWM2OD13LkSwOlkyKM7:TR?= NFnEOppUSU6JRWK=
LP-1 M3Gwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDGTWM2OD13LkSxNlkyKM7:TR?= MnvvV2FPT0WU
NCI-SNU-16 NX3hNIFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTVwNkSwO|Qh|ryP M1rVUnNCVkeHUh?=
LU-65 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwN{[zO|Mh|ryP NYLRXHZNW0GQR1XS
CW-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrHZlVHUUN3ME21Mlg2QTV7IN88US=> NXLTVJh7W0GQR1XS
WSU-NHL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTVwOUWxO|Qh|ryP M2LWNnNCVkeHUh?=
IST-MES1 NXTibGFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTVwOUW0OFMh|ryP M{XHN3NCVkeHUh?=
U-266 NYfieGp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC0PJZ4UUN3ME21Mlk5OjB{IN88US=> M4m5OnNCVkeHUh?=
TALL-1 M3XiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LXeWlEPTB;Nj6xOFY5QCEQvF2= M4fuR3NCVkeHUh?=
Calu-6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTITWM2OD14LkG1N|E3KM7:TR?= NVLtO|VIW0GQR1XS
MMAC-SF MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPUOW5KSzVyPU[uNVg2PTZizszN NFvneWtUSU6JRWK=
NCI-H82 NUL4RmNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTOO4hZUUN3ME22MlIxPDh7IN88US=> MoS0V2FPT0WU
RS4-11 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX0TWM2OD14LkK1PFk4KM7:TR?= NWrYfIlxW0GQR1XS
SNU-C2B MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPBTWM2OD14LkSwPVY6KM7:TR?= NXzIW4V1W0GQR1XS
BOKU NWLlXJF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZwNEe1PVch|ryP MkT6V2FPT0WU
C8166 NWnpTm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTZwNUW5NVIh|ryP MoHmV2FPT0WU
D-247MG M2\tNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXCe|UzUUN3ME23MlA1OzR5IN88US=> MWLTRW5ITVJ?
EW-18 NILRUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTdwMEeyPVIh|ryP MUTTRW5ITVJ?
KG-1 M1;pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHWb3I1UUN3ME23MlYzPzN6IN88US=> MlfpV2FPT0WU
REH MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXMTWM2OD15Lk[4NVA6KM7:TR?= MmTFV2FPT0WU
U-698-M M2XyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHBTWM2OD15Lki0N|E2KM7:TR?= M3;pXnNCVkeHUh?=
KP-N-RT-BM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTdwOUOwNlkh|ryP NXrOUlFkW0GQR1XS
MS-1 NEK3bYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTdwOU[wOFEh|ryP M4fPTHNCVkeHUh?=
SNU-C1 NGnoVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnFc2dKSzVyPUeuPVgyQTJizszN NV:0[nB5W0GQR1XS
SK-MM-2 NVTqfI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rhPWlEPTB;OD6yOlA3PSEQvF2= MoP0V2FPT0WU
LAN-6 NX;GTVZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRThwM{CwNFEh|ryP NYjHUIZIW0GQR1XS
NEC8 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHSRYVVUUN3ME24MlMxPjlzIN88US=> MlfDV2FPT0WU
NCI-H1770 NXz2VHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDmTmxKUUN3ME24MlM5ODB{IN88US=> MX;TRW5ITVJ?
D-336MG M4rJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrVZlFoUUN3ME24MlQxOTF4IN88US=> NInOUlBUSU6JRWK=
COLO-829 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH6NolKSzVyPUiuOFg5PzlizszN Mn3xV2FPT0WU
LS-513 NGDNbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\s[2lEPTB;OD61PVU6QSEQvF2= M3iy[HNCVkeHUh?=
YT M4HPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRThwNkK0Nlch|ryP NWe1Nm5yW0GQR1XS
EW-24 NHPOR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3JUWFKSzVyPUiuO|Y2PCEQvF2= MUXTRW5ITVJ?
IST-SL1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnzTWM2OD16Lki2OVQ{KM7:TR?= MlnMV2FPT0WU
CA46 M3LDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRThwOUWwPVgh|ryP NWLzTJNIW0GQR1XS
NCI-H1838 M{LPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXiTWM2OD16Lkm4OlAzKM7:TR?= NUPIPZRTW0GQR1XS
NCI-H719 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrlTWM2OD17LkK1Nlc6KM7:TR?= NHfC[HJUSU6JRWK=
HCE-T M1jOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm1XpZDUUN3ME25MlMxQDVzIN88US=> MUPTRW5ITVJ?
A498 NH;Fc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojjTWM2OD17LkO2NVI1KM7:TR?= MXvTRW5ITVJ?
LB831-BLC M{m4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETtZY5KSzVyPUmuO|Y2OjFizszN M171d3NCVkeHUh?=
SKM-1 Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTlwOEW5OlMh|ryP NIDFSJNUSU6JRWK=
THP-1 NULIeoZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLLTWM2OD17Lkm2PVE5KM7:TR?= MnT3V2FPT0WU
SHP-77 NXHpbY0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj6TWM2OD1zMD60NFch|ryP NXf4OFM6W0GQR1XS
EW-3 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[yOVNNUUN3ME2xNE43Ojh7IN88US=> MX;TRW5ITVJ?
KY821 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXsZm1YUUN3ME2xNE44PjNizszN NXLtPFBKW0GQR1XS
NCI-SNU-1 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O4RWlEPTB;MUGuNFIyPyEQvF2= MXvTRW5ITVJ?
HCC2218 M{jyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFzLkO5PFYh|ryP NEnBXJpUSU6JRWK=
IM-9 NX3sdVdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFzLkWxNFYh|ryP M1vzcHNCVkeHUh?=
NCI-H889 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHkTWM2OD1zMT61N|E{KM7:TR?= M2\mU3NCVkeHUh?=
HDLM-2 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[2bIxKSzVyPUGyMlQyPTlizszN M4DUTnNCVkeHUh?=
LB2518-MEL NYnZSG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnU[2pOUUN3ME2xNk43QDF3IN88US=> MVvTRW5ITVJ?
NCI-H23 NVjGXFV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPmdFVZUUN3ME2xN{4zPDJ3IN88US=> NFjONnpUSU6JRWK=
NB17 NUfp[2F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXD[YVRUUN3ME2xN{41PTd7IN88US=> NGS2OI5USU6JRWK=
NCI-H322M MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ieYd6UUN3ME2xOE41ODZ6IN88US=> NFywWXRUSU6JRWK=
SUP-T1 NXv5S|A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr2TI5KSzVyPUG0MlQyOyEQvF2= MoTFV2FPT0WU
ES3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF3LkC3NFMh|ryP MUnTRW5ITVJ?
ES5 NVPtWGFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHPTWM2OD1zNT6wO|g4KM7:TR?= NXP3SVl3W0GQR1XS
NCI-H1650 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn3OIlXUUN3ME2xOU41QTd7IN88US=> MofZV2FPT0WU
NCI-H226 NGO5c5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnXTWM2OD1zNT64O|Y5KM7:TR?= MV\TRW5ITVJ?
COR-L88 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjDZmVKSzVyPUG2MlMyPCEQvF2= NI\nVZhUSU6JRWK=
SCC-15 NWjGd3hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rOXGlEPTB;MU[uN|g3QSEQvF2= M4HUTnNCVkeHUh?=
GOTO NEjxcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT5TWM2OD1zNj60O|k{KM7:TR?= MkDBV2FPT0WU
SIMA MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DtOWlEPTB;MU[uOFgxOiEQvF2= NIOzWmJUSU6JRWK=
NCI-H1299 M{TFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF5LkG1PVEh|ryP NHPIXplUSU6JRWK=
NCI-H1581 M1rwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF5LkSyNVkh|ryP MkPtV2FPT0WU
MHH-NB-11 NInhPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXITWM2OD1zNz65Olg{KM7:TR?= M1fUZXNCVkeHUh?=
MFM-223 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;KNpVGUUN3ME2xPE4xPTN6IN88US=> MV\TRW5ITVJ?
ES7 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF6LkW0N|Eh|ryP MYXTRW5ITVJ?
JVM-3 NVy5VFNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF6LkexO{DPxE1? MlOyV2FPT0WU
RL MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uwNWlEPTB;MkCuN|g5KM7:TR?= NHj5U2pUSU6JRWK=
EC-GI-10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\pR45KSzVyPUKxMlIxPDFizszN NIj6Zm1USU6JRWK=
LNCaP-Clone-FGC NUX4XWQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJzLk[3Olgh|ryP NGTRSmJUSU6JRWK=
IMR-5 NV7KZ3NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDoTWM2OD1{MT64OFk1KM7:TR?= Mm\WV2FPT0WU
KP-N-YS NEnnTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jSUmlEPTB;MkGuPFc2KM7:TR?= MlPpV2FPT0WU
Mo-T NX3nOoVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjOTWM2OD1{Mj6yNVg2KM7:TR?= M2LsfHNCVkeHUh?=
NCI-H128 NFriTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K4XGlEPTB;MkOuOVg2OyEQvF2= MV\TRW5ITVJ?
RH-1 MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y1W2lEPTB;MkOuO|g3PiEQvF2= MVTTRW5ITVJ?
NCI-H2171 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf6[IRKSzVyPUK0MlI1QDVizszN NV;Lc24yW0GQR1XS
RPMI-8866 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETqSlFKSzVyPUK2Mlc1OiEQvF2= NYjuWHJmW0GQR1XS
SK-N-FI MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJ5LkO4NVEh|ryP M3i3NHNCVkeHUh?=
LOXIMVI NW[xdGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7RNW1KSzVyPUK3MlgxPTFizszN MULTRW5ITVJ?
P31-FUJ M1:yR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfhdnNKSzVyPUOxMlU{PzRizszN NGjX[nZUSU6JRWK=
KMS-12-PE NInMenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jnbWlEPTB;NEmuOVMxOiEQvF2= MWrTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID